Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01RNA
|
|||
| Former ID |
DIB019718
|
|||
| Drug Name |
desmosterol
|
|||
| Synonyms |
DESMOSTEROL; 24-Dehydrocholesterol; 313-04-2; UNII-ANP93865R8; cholest-5,24-dien-3beta-ol; Cholesta-5,24-dien-3beta-ol; NSC 226126; CHEBI:17737; 3beta-cholesta-5,24-dien-3-ol; ANP93865R8; (3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylhept-5-en-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol; Cholesta-5,24-dien-3-ol; desmesterol; EINECS 206-236-2; 24-dehydro Cholesterol; 24,25-Dehydrocholesterol; AC1L97ME; Cholesta-5,24-dien-3b-ol; 5,24-Cholestadien-3beta-ol; 5,24-Cholestadien-3
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL
|
||
| Formula |
C27H44O
|
|||
| Canonical SMILES |
CC(CCC=C(C)C)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)O)C)C
|
|||
| InChI |
1S/C27H44O/c1-18(2)7-6-8-19(3)23-11-12-24-22-10-9-20-17-21(28)13-15-26(20,4)25(22)14-16-27(23,24)5/h7,9,19,21-25,28H,6,8,10-17H2,1-5H3/t19-,21+,22+,23-,24+,25+,26+,27-/m1/s1
|
|||
| InChIKey |
AVSXSVCZWQODGV-DPAQBDIFSA-N
|
|||
| CAS Number |
CAS 313-04-2
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
4928, 4266377, 8144027, 10298383, 15978228, 24894033, 36883775, 52670367, 57394893, 57403092, 99300578, 103637422, 104620858, 126524635, 127466210, 135651470, 137237337, 138128789, 138613691, 162221242, 164815728, 179293074, 184544358, 198962901, 223703363, 224772242, 226520608, 252363923, 252551927, 252669467
|
|||
| ChEBI ID |
CHEBI:17737
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Farnesoid X-activated receptor (FXR) | Target Info | Agonist | [2] |
| Oxysterols receptor LXR-alpha (NR1H3) | Target Info | Agonist | [3] | |
| Oxysterols receptor LXR-beta (NR1H2) | Target Info | Agonist | [3] | |
| KEGG Pathway | Bile secretion | |||
| PPAR signaling pathway | ||||
| Non-alcoholic fatty liver disease (NAFLD) | ||||
| Hepatitis C | ||||
| Pathway Interaction Database | RXR and RAR heterodimerization with other nuclear receptor | |||
| Reactome | Nuclear Receptor transcription pathway | |||
| Recycling of bile acids and salts | ||||
| PPARA activates gene expression | ||||
| Endogenous sterols | ||||
| WikiPathways | SREBP signalling | |||
| Nuclear Receptors | ||||
| Nuclear Receptors in Lipid Metabolism and Toxicity | ||||
| Nuclear Receptors Meta-Pathway | ||||
| Farnesoid X Receptor Pathway | ||||
| Drug Induction of Bile Acid Pathway | ||||
| PPAR Alpha Pathway | ||||
| Liver X Receptor Pathway | ||||
| Adipogenesis | ||||
| SREBF and miR33 in cholesterol and lipid homeostasis | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2748). | |||
| REF 2 | Identification of farnesoid X receptor beta as a novel mammalian nuclear receptor sensing lanosterol. Mol Cell Biol. 2003 Feb;23(3):864-72. | |||
| REF 3 | Sterol intermediates from cholesterol biosynthetic pathway as liver X receptor ligands. J Biol Chem. 2006 Sep 22;281(38):27816-26. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.